Anzeige
Meldung des Tages: Gold bei 5.250 USD – Dieser 37-Mio.-€-Goldentwickler sitzt auf einem möglichen $2-Milliarden-Projekt!!

Vivoryon Therapeutics News

Aktie
WKN:  A2QJV6 ISIN:  NL00150002Q7 US-Symbol:  PRBGF Land:  Deutschland
1,352 €
-0,016 €
-1,17%
20:28:08 Uhr
Depot/Watchlist
Marktkapitalisierung *
38,58 Mio. €
Streubesitz
51,03%
KGV
-
Index-Zuordnung
-

Vivoryon Therapeutics News

07.01.26 - GlobeNewswire
Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences
Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences
04.12.25 - GlobeNewswire
Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates
Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates
25.11.25 - GlobeNewswire
Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Operational Progress on December 4, 2025
Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Operational Progress on December 4, 2025
06.11.25 - GlobeNewswire
Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025
Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025
03.11.25 - GlobeNewswire
Vivoryon Therapeutics N.V. to Present at Upcoming Conferences
Vivoryon Therapeutics N.V. to Present at Upcoming Conferences
06.10.25 - GlobeNewswire
Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 Million
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, ...
04.09.25 - GlobeNewswire
Vivoryon Therapeutics N.V. Reports H1 2025 Financial Results and Business Updates
Vivoryon Therapeutics N.V. Reports H1 2025 Financial Results and Business Updates
27.08.25 - GlobeNewswire
Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress on September 4, 2025
Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress on September 4, 2025
27.06.25 - GlobeNewswire
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences
24.06.25 - GlobeNewswire
Vivoryon Therapeutics N.V. Reports Outcome of 2025 Annual General Meeting
Vivoryon Therapeutics N.V. Reports Outcome of 2025 Annual General Meeting
17.06.25 - GlobeNewswire
Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress
Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress
11.06.25 - GlobeNewswire
Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational Progress on June 17, 2025
Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational Progress on June 17, 2025
06.06.25 - GlobeNewswire
Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025
Vivoryon Therapeutics N.V. Presents Meta-​analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025
27.05.25 - GlobeNewswire
Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S. Composition of Matter Patent Granted for Varoglutamstat
Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S. Composition of Matter Patent Granted for Varoglutamstat
13.05.25 - GlobeNewswire
Vivoryon Therapeutics N.V. to Hold its 2025 Annual General Meeting on June 24, 2025
Vivoryon Therapeutics N.V. to Hold its 2025 Annual General Meeting on June 24, 2025
29.04.25 - GlobeNewswire
Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update
Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update
24.04.25 - GlobeNewswire
Vivoryon Therapeutics N.V. Signs Financing Agreement for up to EUR 15 Million
Vivoryon Therapeutics N.V. Signs Financing Agreement for up to EUR 15 Million
17.04.25 - GlobeNewswire
Vivoryon Therapeutics N.V. to Report Full Year 2024 Financial Results and Operational Progress on April 29, 2025
Vivoryon Therapeutics N.V. to Report Full Year 2024 Financial Results and Operational Progress on April 29, 2025
04.03.24 - ARIVA.DE Redaktion
Vivoryon und der Rückschlag in der Alzheimer-Forschung: Ein detaillierter Blick auf die VIVIAD-Studie
Ein weiterer Rückschlag für die Alzheimer-​Forschung: Die VIVIAD-​Studie von Vivoryon Therapeutics konnte die gesetzten Ziele nicht erreichen. Was bedeutet dies für die Zukunft der ...

Newssuche

Videos

newspaper
10.03.26 0,00%
Technical Trading: DAX Long Chance
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »